Inhibition of IKK complex - Dual inhibition of IκB kinase 1/2 for cancer therapy

Ref.-Nr. 5028

Keywords: inhibitorische kappa B Kinase, Krebs, Gentherapie, IKK, inhibitory kappa B kinase, cancer, gene therapy, CRISPR/CAS

The invention provides com-positions comprising IKK1 and IKK2 antagonists for use in medical treatments of proliferative disorders, in particular for the treatment of cancer. Most preferred in context of the invention is a gene editing approach for a targeted simultaneous knockout of the genes of IKK1 and IKK2 in a cell associated with the proliferative disorder. Simultaneous CRISPR/Cas9-mediated knockout of IKBKA (IKK1) and IKBKB (IKK2) resulted in cells highly sensitized for programmed cell death (apoptotic/necroptotic) after exposure to tumor necrosis factor (TNF)-α. This effect was not observable in single knockouts for either IKK1 or IKK2. Targeting of IKK1 and IKK2 simultaneously, preferably on the genome level, therefore opens up new therapeutic avenues to tackle proliferative disorders such as cancer. Hence, the present methods and compositions provide a means for the selective induction of apoptosis in cells associated with a proliferative disorder, such as tumor cells.

Vorteile

  • Novel gene therapy for Cancer
  • Novel screening strategy
  • Therapy option for drug-resistant cancers

Kommerzielle Anwendung

Novel gene therapy and a novel drug screening concept are offered for licensing.

Aktueller Stand

In case of interest we are pleased to inform you about the patent status.

Relevante Veröffentlichungen

Slotta, C., et al. CRISPR/Cas9-mediated deficiency of human IKBK1/IKBK2 leads to TNFα-induced programmed cell death. In preparation.

Slotta, C., et al. (2017) CRISPR/Cas9-mediated knockout of c-REL in HeLa cells results in profound defects of the cell cycle. PLoS ONE 12(8): e0182373.

Karin, M., et al. (2002) NF-kappaB in cancer: from innocent bystander to major culprit. Nat. Rev. Cancer 2(4): 301-10.

Eine Erfindung der Uni Bielefeld.

Prof. Dr. Frank Entschladen

fe@provendis.info
+49 208 9410520